J Psychiatry Neurosci 2021;46(3):E369-E370 | PDF
Nicolas Garel, MD; Kyle T. Greenway, MD, MSc; Karim Tabbane, MD; Ridha Joober, MD, PhD
Affiliations: From the Psychiatry residency program, PGY4, McGill University, Montreal, Canada (Garel, Greenway); the Department of Psychiatry, McGill University, Montreal, Canada (Tabbane); and the Douglas Mental Health University Institute, Montreal, Canada (Joober).
Competing interests: R. Joober sits on the advisory boards and speakers’ bureaus of Pfizer, Janssen Ortho, BMS, Sunovion, Otsuka, Lundbeck, Perdue and Myelin; he has received grant funding from them and from AstraZeneca and HLS. He has received honoraria from Janssen Canada, Shire, Lundbeck, Otsuka, Pfizer and Perdue for CME presentations and royalties from Henry Stewart talks. He is co-editor-in-chief of JPN, but he was not involved in the review of or decision to accept this manuscript for publication. No other competing interests were declared.
Content licence: This is an Open Access article distributed in accordance with the terms of the Creative Commons Attribution (CC BY-NC-ND 4.0) licence, which permits use, distribution and reproduction in any medium, provided that the original publication is properly cited, the use is non-commercial (i.e. research or educational use), and no modifications or adaptations are made. See: https://creativecommons.org/licenses/by-nc-nd/4.0/